HNGZ.Y Stock Overview
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 2/6 |
| Past Performance | 1/6 |
| Financial Health | 5/6 |
| Dividends | 4/6 |
Hangzhou Tigermed Consulting Co., Ltd Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CN¥4.20 |
| 52 Week High | CN¥7.78 |
| 52 Week Low | CN¥4.20 |
| Beta | 0.69 |
| 1 Month Change | 0% |
| 3 Month Change | -4.55% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -67.06% |
Recent News & Updates
Recent updates
Shareholder Returns
| HNGZ.Y | US Life Sciences | US Market | |
|---|---|---|---|
| 7D | 0% | 3.7% | 2.2% |
| 1Y | n/a | 1.6% | 22.8% |
Return vs Industry: Insufficient data to determine how HNGZ.Y performed against the US Life Sciences industry.
Return vs Market: Insufficient data to determine how HNGZ.Y performed against the US Market.
Price Volatility
| HNGZ.Y volatility | |
|---|---|
| HNGZ.Y Average Weekly Movement | n/a |
| Life Sciences Industry Average Movement | 6.8% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: HNGZ.Y has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine HNGZ.Y's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 9,455 | Xiaochun Cao | www.tigermedgrp.com |
Hangzhou Tigermed Consulting Co., Ltd provides contract research organization services in the People’s Republic of China and internationally. It operates in Clinical Trial Solutions, and Clinical-related and Laboratory Services segments. The company offers preclinical development services, including medicinal chemistry, compound screening, DMPK, safety and toxicology, bioanalytical, and formulation research and development services; and clinical development services, such as medical writing, clinical monitoring, regulatory affairs, data management and statistical analysis, clinical development strategy, site management, subject recruitment, medical device/ in vitro diagnostics, multi-region clinical trial, and vaccine clinical trial services.
Hangzhou Tigermed Consulting Co., Ltd Fundamentals Summary
| HNGZ.Y fundamental statistics | |
|---|---|
| Market cap | US$5.88b |
| Earnings (TTM) | US$317.07m |
| Revenue (TTM) | US$1.02b |
19.8x
P/E Ratio6.2x
P/S RatioIs HNGZ.Y overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| HNGZ.Y income statement (TTM) | |
|---|---|
| Revenue | CN¥7.33b |
| Cost of Revenue | CN¥4.41b |
| Gross Profit | CN¥2.92b |
| Other Expenses | CN¥637.95m |
| Earnings | CN¥2.28b |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
Mar 29, 2024
| Earnings per share (EPS) | 2.63 |
| Gross Margin | 39.83% |
| Net Profit Margin | 31.13% |
| Debt/Equity Ratio | 12.4% |
How did HNGZ.Y perform over the long term?
See historical performance and comparison